Outcome Prediction in Hodgkin Lymphoma by Low-Density Gene Expression Profiling of Formalin Fixed Paraffin Embedded Tissues: A Correlative Study of Inter-Group Trial E2496
16 Years
N/A
Both
Lymphoma
Trial Information
Outcome Prediction in Hodgkin Lymphoma by Low-Density Gene Expression Profiling of Formalin Fixed Paraffin Embedded Tissues: A Correlative Study of Inter-Group Trial E2496
OBJECTIVES:
- To explore the predictive power of a gene expression-based multi-gene predictor in
classical Hodgkin lymphoma (cHL) with the potential to change clinical practice by
basing treatment decisions on biological markers.
OUTLINE: Archived tissue samples are analyzed for gene expression profile using NanoString
technology. Results are then compared with patients' treatment outcomes, including
failure-free survival and overall survival.
PROJECTED ACCRUAL: A total of 306 patients from ECOG-2496 (training cohort) and 87 patients
treated with ABVD in other trials (validation cohort) will be accrued for this study.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Training cohort: Patients diagnosed with locally extensive and advanced stage
classical Hodgkin lymphoma (cHL) and treated with doxorubicin, bleomycin,
vinblastine, and dacarbazine (ABVD) or mechlorethamine, doxorubicin hydrochloride,
vinblastine, vincristine, bleomycin, etoposide, and prednisone (Stanford V)
- Pretreatment formalin-fixed, paraffin-embedded tissue (FFPET) from patients
enrolled on the randomized phase III ECOG-2496 clinical trial
- Validation cohort: Patients with advanced-stage cHL treated with ABVD at the British
Columbia Cancer Agency (BCCA)
- Pretreatment FFPET available
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Potential of gene expression profiling in changing treatment decision in cHL
Safety Issue:
No
Principal Investigator
Randall D. Gascoyne, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
British Columbia Cancer Agency
Authority:
United States: Federal Government
Study ID:
CDR0000720334
NCT ID:
NCT01505712
Start Date:
December 2011
Completion Date:
Related Keywords:
- Lymphoma
- stage I adult Hodgkin lymphoma
- stage II adult Hodgkin lymphoma
- stage III adult Hodgkin lymphoma
- stage IV adult Hodgkin lymphoma
- Hodgkin Disease
- Lymphoma
Name | Location |
|---|
